Clinical trial
The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China
NCT05046314 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 12, 2024
- Completion date
- February 5, 2025
- Enrollment
- 15 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.